Printer Friendly

Immunoprotein Diagnostic Testing Market to reach USD 10.3bn by 2025, Research and Markets Forecasts.

M2 PHARMA-August 23, 2017-Immunoprotein Diagnostic Testing Market to reach USD 10.3bn by 2025, Research and Markets Forecasts

(C)2017 M2 COMMUNICATIONS

- The global immunoprotein diagnostic testing market is anticipated to reach USD 10.3bn by 2025, according to a report from Dublin-based Research and Markets.

This growth can be attributed to the rising incidence of chronic diseases.

According to American Heart Association's 2017 statistics, nearly 790,000 people experience heart attack every year in the US In addition, stroke is responsible for one in every 20 deaths in the US.

Hence, WHO is also taking initiatives to reduce the risk of cardiovascular diseases.

As a result of the aforementioned factors, the demand for immunoprotein diagnostics is expected to rise in order to facilitate rapid diagnosis.

According to WHO, nearly 1.69m deaths due to lung cancer were registered in 2015 throughout the world.

Hence, fast and accurate diagnosis of such chronic diseases has become important to reduce the high mortality rate. Immunoprotein diagnostic devices and reagents have proved to be highly effective in rapidly detecting chronic diseases.

Technological advancements in the field of immunoprotein diagnostics have led to introduction of novel products.

For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyser that facilitates complete sample processing.

It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.

In 2016, immunoglobulin tests dominated the market owing to their frequent usage by healthcare professionals for diagnosing infectious or autoimmune disorders.

C-Reactive Protein tests held a significant market share in 2016 due to the broad product portfolio of these assays and reagents.

Infectious disease testing held largest market share in 2016 owing to the increasing prevalence of infectious diseases and high applications of immunoprotein tests.

Enzyme-based immunoassays dominated the market in 2016 due to their frequent usage and availability of large number of products that possess this technology.

Chemiluminescence assay is anticipated to witness highest growth over the forecast period due to its high sensitivity and specificity.

North America dominated the market in 2016 due to rising prevalence of cancer and increase in mortality due to cancer-related diseases and favorable healthcare reimbursement scenario in the US.

Some of the key players in this market are Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche AG; Abbott Laboratories; Enzo Biochem, Inc.; Thermo Fisher Scientific, Inc.; DiaSorin S.p.A; bioMerieux SA; and Siemens Healthcare GmbH.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 23, 2017
Words:409
Previous Article:Innoviva Completes Refinancing of Notes, Closes USD 250m Term B Loan.
Next Article:Christus Health Joins TriNetX Health Research Network to Accelerate Clinical Trial Efforts.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters